Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

103.36 +0.79 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
From Grabar Law Office
Via GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); and Maison Solutions
From Grabar Law Office
Via GlobeNewswire
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)
Via Benzinga
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Stocks Edge Higher Despite Trade, Economic Jitters
Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data. 
Via Talk Markets
Topics Stocks / Equities
Why Shares of Axsome Therapeutics Slumped Today
Via The Motley Fool
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week
The company posted mixed results for its depression treatment, noting it appears to work in a smaller patient group. 
Via Investor's Business Daily
Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder
Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients supports plans for a new study in 2025. 
Via Benzinga
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views
Via Benzinga
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
Via The Motley Fool
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.
The company is working on a non-stimulant approach to treating ADHD. 
Via Investor's Business Daily
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal
Axsome's solriamfetol met primary and key secondary endpoints in a Phase 3 ADHD trial, showing significant symptom reduction and a favorable safety profile. 
Via Benzinga
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer’s Disease Agitation Supporting NDA Submission
Supplemental New Drug Application (sNDA) submission anticipated in 3Q 2025 
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
Axsome's Symbravo outperformed oral CGRP inhibitors in a Phase 3 trial, improving migraine pain relief, symptom control, and return to daily activities. 
Via Benzinga
Axsome Therapeutics Announces SYMBRAVO® (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride
CEO Herriot Tabuteau struck an optimistic tone, citing strong commercial growth, a rapidly advancing pipeline, and the recent U.S. approval of Symbravo for migraine treatment. 
Via Stocktwits
US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday?
Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday. 
Via Benzinga
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025. 
Via Benzinga
Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript
AXSM earnings call for the period ending December 31, 2024. 
Via The Motley Fool
Topics Earnings
Axsome Therapeutics Revenue Surges 66%
Axsome Therapeutics demonstrated robust revenue growth in Q4 2024, outpacing expectations despite higher-than-anticipated losses. 
Via The Motley Fool
Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
Earnings Scheduled For February 18, 2025
Via Benzinga
This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy?
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.